TY - JOUR AU - M.V. Khaitovych PY - 2015/10/27 Y2 - 2024/03/28 TI - PERSONALIZED ANTIHYPERTENSIVE THERAPY JF - Medical Science of Ukraine (MSU) JA - Med. Sci. of Ukr. VL - 11 IS - 1-2 SE - REVIEW DO - UR - https://msu-journal.com/index.php/journal/article/view/157 AB - Hypertension is a high risk cardiovascular factor. It is well known that only of 25-30 % patients with hypertension could attain an adequate control of blood pressure.This review article contains literature data and own research results which deals with problems of hypertension pharmacogenetics. It is described up-to-date data of genetic factor impact on pharmacokinetics and pharmacodynamics of various types of antihypertensive drugs.It is proven reasonable definition of gene polymorphism CYP2D6 and CYP3A4 in patients with aim to prevent adverse effects of lipophilic beta-blockers and dihydropyridine’s derivatives of calcium-channel blocking drugs respectively.The article points out on sensitivity of thiazide diuretics in patients with DD genotype of ACE and Gly460 genotype of gene α-adducin; high hydrochlorothiazide effectiveness of TT β3 genotype subunits of G-protein gene.Beta-adrenoreceptor blocking drugs have shown various effectiveness in patients with vary genotypes of 7 exon eNOS and ADRB1 gene, ACE inhibitors - depends on I/D polymorphism of 16 intron of ACE gene, Gly460Trp polymorphism of α-adducin gene, M235T polymorphism of gene angiotensinogen; receptor antagonists to angiotensin II - depends on 16 intron of ACE gene, 344 C/T polymorphism of aldosterone synthase gene, A1166C polymorphism of AGTR1 gene.Introduction of the principles of evidence-based research into pharmacogenetics studying will allow concluding definitively about effect of candidate-gene polymorphisms and microRNA expression on the efficacy of antihypertensive drugs administration.Pharmacogenetics-based personalization could improve hypertension pharmacotherapy in patients to maximum safe and effective. ER -